ClinicalTrials.gg
CompletedNCT04051463Updated Oct 19, 2021Results posted

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

A Phase 2/3 interventional study of Netarsudil Ophthalmic Solution and Placebo in Fuchs Endothelial Dystrophy, sponsored by Price Vision Group. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-19.

Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Fuchs' Endothelial Dystrophy with a site in United States — 9 open to participants now, 10 under way, 1 of them phase 3. Fuchs' Endothelial Dystrophy · United States.

Enrollment
21st of 32
29 · median 44
Started
2019
with 3 others
Phase 2/3
3 of 40
none open now
Registered
18th of 40
by date
Lead sponsor
2 of 40
Price Vision Group

Among the 40 studies in Fuchs' Endothelial Dystrophy with a site in United States, this one is the 21st largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2019, is one of 3 in phase 2/3, and was the 18th registered.

Fuchs' Endothelial Dystrophy

92 studies on the registry are indexed under Fuchs' Endothelial Dystrophy; 27 are open to participants now.

Browse Fuchs' Endothelial Dystrophy studies →

Open to participants now

9 of the 40 studies in Fuchs' Endothelial Dystrophy with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Fuchs' Endothelial Dystrophy studies recruiting now, 16 (73%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Fuchs' Endothelial Dystrophy with a site in United States, or all of them as a file.
02

Study summary

The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.

03

Conditions studied

  • Fuchs Endothelial Dystrophy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Male or female patient diagnosed with FECD and corneal edema evident by slit lamp exam and/or corneal tomography.
  • Patient is able and willing to administer eye drops.
  • Patient is able to comprehend and has signed the form.

Exclusion criteria

Exclusion Criteria:

  • Active intraocular inflammation, corneal ulceration, keratitis, or conjunctivitis.
  • Known sensitivity to any of the ingredients in the study medications.
  • Abnormal eyelid function.
  • History of herpetic keratitis.
  • History of non-compliance with using prescribed medication.
  • Current or planned pregnancy within the study duration.
  • Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study.
  • Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Netarsudil

    A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.

    Drug: Netarsudil Ophthalmic Solution

  • Placebo comparator
    Placebo

    A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.

    Drug: Placebo

Interventions

  • Netarsudil eye drops instilled once daily

    Also known as: Rhopressa

  • DrugPlacebo

    Placebo eye drops instilled once daily

    Also known as: Rhopressa vehicle without active ingredient

06

What researchers measure

Primary outcomes

  1. Change in Central Corneal Thickness

    Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline

    Time frame: 1 month

Secondary outcomes

  1. Change in Corrected Distance Visual Acuity (CDVA)

    Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)

    Time frame: 3 months

07

Results

Posted Sep 24, 2021

Participant flow

Participant flow — Overall Study
MilestoneNetarsudilPlacebo
Started1514
Completed1313
Not completed21

Outcome measures

PrimaryChange in Central Corneal Thickness

Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline

Time frame:
1 month
Reported as:
Mean · microns
Change in Central Corneal Thickness
micronsNetarsudilPlacebo
Change in Central Corneal Thickness-23 (-32 to -13)-2 (-9 to 5)
SecondaryChange in Corrected Distance Visual Acuity (CDVA)

Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)

Time frame:
3 months
Reported as:
Mean · lines on the eye chart
Change in Corrected Distance Visual Acuity (CDVA)
lines on the eye chartNetarsudilPlacebo
Change in Corrected Distance Visual Acuity (CDVA)1.9 (0.8 to 3)0.3 (-0.7 to 1.3)

Adverse events

Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil0/15 (0%)0/15 (0%)6/15 (40%)
Placebo0/14 (0%)0/14 (0%)3/14 (21.4%)
Most frequent other events
Most frequent other events
EventNetarsudilPlacebo
conjunctival hyperemiaEye disorders6/153/14
ocular irritationEye disorders2/151/14
lacrimationEye disorders0/151/14
glareEye disorders1/150/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)NetarsudilPlaceboTotal
Mean68 ± 569 ± 768 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)NetarsudilPlaceboTotal
Female9918
Male6511
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NetarsudilPlaceboTotal
White, non-Hispanic151429
Region of Enrollment
Region of Enrollment(participants)NetarsudilPlaceboTotal
United States151429
08

Study locations

1 site
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
09

References and documents

Publications

  • Price MO, Price FW Jr. Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy. Am J Ophthalmol. 2021 Jul;227:100-105. doi: 10.1016/j.ajo.2021.03.006. Epub 2021 Mar 15. PubMed 33737034 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Jul 2020, 10 months.

Results were first posted in Sep 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2019
First posted
Aug 9, 2019
StartActual
Aug 5, 2019
Primary completionActual
Jul 1, 2020
CompletionActual
Jul 1, 2020
Results first posted
Sep 24, 2021
Last update
Oct 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04051463
Lead sponsor
Price Vision Group
Responsible party
Sponsor
First posted
Aug 9, 2019
Start date
Aug 5, 2019
Primary completion
Jul 1, 2020
Completion
Jul 1, 2020
Results posted
Sep 24, 2021
Last update
Oct 19, 2021

Study contacts

Francis W Price, Jr, MD
principal investigator · Price Vision Group

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion